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KObjectives: The primary objective of the study was to evaluate the
feasibility, reliability, and validity of the Pediatric Quality of Life Inven-
tory™ (PedsQL) 4.0 Generic Core Scales as a patient self-reported
health-related quality of life measurement instrument in pediatric
patients with attention-deficit/hyperactivity disorder (ADHD) and
physician-diagnosed comorbid psychiatric disorders being seen in
a pediatric psychiatric clinic. The secondary objective was to evaluate
parent proxy-reported PedsQL in this population. Methods: One hun-
dred seventy-nine children with ADHD and comorbid psychiatric dis-
orders ages 5 to 18 years and 181 parents completed the PedsQL 4.0
Generic Core Scales and parents also completed the Vanderbilt ADHD
Diagnostic Rating Scales. Known-groups discriminant validity compar-
isons were made between the sample of pediatric patients with ADHD
and comorbid psychiatric disorders and healthy, cancer, and type 1
diabetes samples. Results: The PedsQL evidenced minimal missing re-
sponses for patient self-report and parent proxy-report (0.2% and 0.5%,
respectively), demonstrated no significant floor or ceiling effects, and
achieved excellent reliability for the Total Scale Score (  0.85 patient
self-report, 0.92 parent proxy-report). Pediatric patients with ADHD
and comorbid psychiatric disorders and their parents reported statis-
tically significantly worse PedsQL scores than healthy children, with
dem
arges
ture
al So
doi:10.1016/j.jval.2010.10.031arge effect sizes across all domains, supporting known-groups dis-
riminant validity. Pediatric patients with ADHD and comorbid psychi-
tric disorders and their parents reported worse PedsQL scores com-
ared to pediatric patients with cancer and diabetes with the exception
f physical health, in which pediatric cancer patients manifested lower
hysical health, indicating the relative severe impact of ADHD and
omorbid psychiatric disorders. More severe ADHD symptoms were
enerally associated with more impaired PedsQL scores, supporting
onstruct validity. Conclusions: These data demonstrate the feasibil-
ty, reliability, and validity of patient self-reported PedsQL 4.0 Generic
ore Scales in this high risk population of pediatric patients and high-
ight the profound negative impact of ADHD and comorbid psychiatric
isorders on generic health-related quality of life, comparable to or
orse than serious pediatric chronic physical diseases.
eywords: ADHD, PedsQL, attention-deficit/hyperactivity disorder, chil-
dren, comorbidity, health-related quality of life, patient reported out-
comes.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most
prevalent childhood chronic disorders, affecting an estimated 3% to
7% of school-aged children [1]. Symptoms of ADHD include impul-
sivity, a developmentally inappropriate activity level, low frustration
tolerance, poor organization of behavior, distractibility, and an in-
ability to sustain attention and concentration [2,3].
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Published by Elsevier Inc.The past 10 years have witnessed a significant increase in the
utilization of health-related quality of life (HRQOL) instruments in
pediatric patients with ADHD [4]. HRQOL is a multidimensional
construct, consisting at the minimum of the physical, psycholog-
ical (including emotional and cognitive), and social health dimen-
sions delineated by the World Health Organization [5,6]. A number
of authors have argued that improving HRQOL is the ultimate goal
of health care [7].
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522 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 2 1 – 5 3 0Legislative changes during the past several years, including the
Pediatric Exclusivity Provision of the Best Pharmaceuticals for
Children Act and the Pediatric Research Equity Act, have estab-
lished voluntary and mandatory guidelines for drug studies in
children that have resulted in a significant growth in clinical trials
for pediatric patients. Despite the above-mentioned pediatric ini-
tiatives, which have created the opportunity for children to be
included in clinical trials, when evaluating the health outcomes of
treatments in the vast majority of pediatric clinical trials to date,
pediatric patients have not been provided the right to self-report
on matters pertaining to their health and well-being [8].
In clinical trials for pediatric patients with ADHD, treatment
esponse often centers on symptom reduction measured through
ehavioral rating scales completed by a child’s parents and teach-
rs [9]. These behavior rating scales, such as the Conners’ Rating
cales, are restricted in their ability to evaluate a child’s function-
ng broadly since they are specific for behavioral characteristics of
DHD (e.g., inattention, hyperactivity, cognitive problems, oppo-
itional behavior, anxiety, and social problems). In addition, many
f these behavior rating scales are not able to evaluate a young
hild’s perspective regarding his/her functioning because they
nly provide parent and teacher reports for young children.
This practice stands in sharp contrast to the recent Food and Drug
dministration guidance for industry for evaluating patient-re-
orted outcome (PRO) instruments as health outcomes in clinical
rials in which the Food and Drug Administration definitely states
hat “some treatment effects are known only to the patient” [5]. Thus,
hile it has been readily acknowledged in clinical trials for adult
atients that PROs are patient self-reported outcomes, this has not
eceived the same level of recognition in clinical trials for pediatric
atients [8]. The emerging paradigm shift toward PROs in clinical
rials has provided the opportunity to underscore the importance
nd essential need for pediatric patient self-reported health out-
omes as efficacy outcomes in pediatric ADHD clinical trials. Pediat-
ic patient self-reported generic HRQOL measurement can compli-
ent ADHD behavior rating scales and provide a more thorough
nderstanding of the patient’s perspective on the impact of ADHD
nd its treatment on their health and well-being [4].
Measurement of HRQOL in ADHD is complicated by the fact
hat there is a high frequency of comorbid (coexisting) psychiatric
isorders in children with ADHD [10,11]. Comorbid psychiatric dis-
rders often associated with ADHD include oppositional defiant
isorder, conduct disorder, depression, bipolar disorder, anxiety,
ic disorders, obsessive compulsive disorder, learning disabilities,
nd mental retardation [2]. ADHD symptoms are associated with
mpairments across multiple domains, including emotional, so-
ial, and school functioning [12]; the coexistence of ADHD with
ther psychiatric disorders in children has been associated with
reater severity of ADHD symptoms and behavioral problems, and
ore substantial impairments in psychosocial functioning [10].
stimates of comorbid oppositional defiant disorder/conduct dis-
rder range from 30% to 50% of cases; lifetime rates of comorbid
epression in children with ADHD range from 29% to 45%; children
ith ADHD with comorbid psychiatric disorders have been found
o require increased psychiatric treatment [12]. Thus, the high in-
idence of comorbid psychiatric disorders in pediatric patients
ith ADHD further increases the significant at risk status for im-
aired HRQOL in this population of children. To our knowledge, no
tudy has ever investigated patient self-reported HRQOL in pedi-
tric patients with ADHD and physician-diagnosed comorbid psy-
hiatric disorders.
Furthermore, studies that have evaluated HRQOL in children
ith ADHD provide an incomplete picture since HRQOL was as-
essed only through parent proxy-report for all but one of the
tudies [13–24]. Although these studies demonstrated the signifi-
ant negative effect of ADHD on HRQOL from the perspective of
arent proxy-report, particularly in terms of psychosocial func-tioning, only the study by Varni and Burwinkle [13] assessed pedi-
atric patient self-reported HRQOL in children with ADHD. How-
ever, this study was a population-based study so children were
identified by their parents as having ADHD, not by a physician. In
addition, information on comorbid psychiatric disorders was un-
available as was information on ADHD symptom severity.
Given the far-reaching psychosocial difficulties associated
with ADHD and comorbid psychiatric disorders, and the docu-
mented discrepancies between child and parent reports in the
general pediatric literature [25,26], documenting the measure-
ment properties of pediatric patient self-reported HRQOL in pa-
tients with ADHD and comorbid psychiatric disorders addresses
an important gap in the empirical literature. As noted in a recent
review [4], “Unfortunately the majority of studies in relation to
child mental health in general and ADHD in specific have used
only parent/carers as informants and not asked the child them-
selves about their QoL.” Thus, pediatric patient self-reported
HRQOL in ADHD continues to be underinvestigated, notably in
pediatric patients with ADHD and comorbid psychiatric disorders.
In fact, in the recent review by Edmund et al. [4], no study was
found in the extant empirical literature that included patient self-
reported HRQOL in pediatric patients with ADHD and comorbid
psychiatric disorders.
The Pediatric Quality of Life Inventory™ (PedsQL) 4.0 Generic
Core Scales [27] has emerged as a widely used generic HRQOL
measure in pediatric chronic health conditions that has resulted
from an extensive iterative process involving numerous patient
and parent focus groups and individual focus interviews, item
generation, cognitive interviewing, pretesting, and subsequent
field testing, with more than 500 peer-reviewed journal publica-
tions and 70 international translations [28]. The PedsQL 4.0 Ge-
neric Core Scales has been increasingly used in pediatric psychi-
atric disorders, demonstrating significant impairments in HRQOL
[13,29] and significant intercorrelations with the Child Behavior
Checklist [30–32] and measures of emotional distress including
the Children’s Depression Inventory [33], the State-Trait Anxiety
Inventory for Children [32], the Revised Children’s Manifest Anxi-
ety Survey [33], and the Social Phobia and Anxiety Inventory for
Children and Short Mood and Feeling Questionnaire [34]. How-
ever, the measurement properties of the PedsQL 4.0 Generic Core
Scales as a patient self-reported measurement instrument in pe-
diatric patients with ADHD and comorbid psychiatric disorders
has not been previously investigated.
Consequently, the primary objective of this study was to
evaluate the feasibility, reliability, and validity of the PedsQL 4.0
Generic Core Scales as a patient self-reported generic HRQOL
measurement instrument in pediatric patients with ADHD and
physician-diagnosed comorbid psychiatric disorders being seen
in a Pediatric Psychiatric Clinic. The secondary objective was to
evaluate the measurement properties of the PedsQL parent
proxy-report version in this population since previous PedsQL
studies did not include pediatric patients with ADHD and co-
morbid psychiatric disorders. This population of pediatric pa-
tients with ADHD treated at a Pediatric Psychiatric Clinic was
specifically selected given that patients being seen in a psychi-
atric clinic manifest a high prevalence of comorbid psychiatric
disorders [35,36].
Based on previous findings [14,20], we hypothesized that
children and adolescents with ADHD and comorbid psychiatric
disorders would demonstrate significantly lower PedsQL scale
scores (effect sizes in the medium to large range) than a
matched sample of healthy children, with the greatest differ-
ences evidenced on psychosocial functioning. We anticipated
that more impaired PedsQL scale scores would be associated
with more severe ADHD symptoms, consistent with previous
findings using parent proxy-report [14,18,20,21]. We also com-
pared the sample of pediatric patients with ADHD and comorbid
i
t
i
y
p
a
p
u
a
o
c
523V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 2 1 – 5 3 0psychiatric disorders to two groups of pediatric patients with
serious chronic physical diseases; that is, cancer and diabetes,
to determine the relative impact of ADHD and comorbid psychi-
atric disorders on patient reported PedsQL scores. Finally, based
on the general pediatric HRQOL literature [25], we hypothesized
that children and their parents would demonstrate moderate
agreement regarding the child’s PedsQL scores, and that par-
ents would report lower mean PedsQL scores than their chil-
dren.
Method
Participants
Participants in this cross-sectional study were 179 children with a
physician diagnosis of ADHD and comorbid psychiatric disorders
ages 5 to 18 years and 181 parents of children with a physician
diagnosis of ADHD and comorbid psychiatric disorders ages 5 to 18
years being seen in a pediatric psychiatric clinic. One hundred
seventy-seven participants had both patient self-report and par-
ent proxy-report PedsQL data; two participants only had patient
self-report and four participants only had parent proxy-report
PedsQL data, which accounts for the differences in sample size
presented in the sociodemographic description of the sample
below.
Measures
PedsQL 4.0 Generic Core Scales
The 23-item PedsQL 4.0 Generic Core Scales encompass
1) physical functioning (eight items); 2) emotional functioning (five
items); 3) social functioning (five items); and 4) school functioning
(five items). The Physical Health Summary Score (eight items) is
the same as the Physical Functioning Scale. To create the Psycho-
social Health Summary Score (15 items), the mean is computed as
the sum of the items divided by the number of items answered in
the Emotional, Social, and School Functioning Scales.
The PedsQL 4.0 Generic Core Scales are comprised of parallel
child self-report and parent proxy-report formats. Child self-
report includes ages 5 to 7 years, 8 to 12 years, and 13 to 18 years.
The items for each of the forms are essentially identical, differing
in developmentally appropriate language. This scale construct
consistency facilitates the evaluation of differences in HRQOL
across and between age groups, as well as the tracking of HRQOL
longitudinally. The instructions ask how much of a problem each
item has been during the past 1 month. A five-point categorical
response scale is utilized across child self-report for ages 8 to 18
years (0 never a problem; 1 almost never a problem; 2 some-
times a problem; 3  often a problem; 4  almost always a prob-
lem). Items are reverse-scored and linearly transformed to a 0 to
100 scale (0 100, 1 75, 2 50, 3 25, 4 0), so that higher scores
ndicate better HRQOL. Scale scores are computed as the sum of
he items divided by the number of items answered. To further
ncrease the ease of use for the young child self-report (ages 5 to 7
ears), the response scale is reworded and simplified to a three-
oint scale (0 not at all a problem; 2 sometimes a problem; 4
lot of a problem), with each response choice anchored to a hap-
y-to-sad faces scale. The instrument takes approximately 5 min-
tes to complete [27]. In this study, only children ages 5 to 18 years
nd their parents completed the PedsQL given the low prevalence
f children with ADHD ages 2 to 4 years seen in the pediatric psy-
hiatric clinic in which data were collected.Vanderbilt ADHD Diagnostic Rating Scales
Parents completed the parent version of the Vanderbilt ADHD Di-
agnostic Rating Scales. Content of the Vanderbilt ADHD Diagnostic
Rating Scales Parent Version has been shown to be consistent with
the Diagnostic and Statistical Manual for Mental Disorders, 4th Edition
diagnosis of ADHD in school-aged children [37], and a single par-
ent rater has been successfully used to identify children with
ADHD in a nationally representative sample [38]. The Vanderbilt
includes a nine-item Inattentive Scale and nine-item Hyperac-
tive/Impulsive Scale. The Total ADHD Symptom Score (18 items)
is a summary score of the Inattentive Scale and Hyperactive/
Impulsive Scale. The Vanderbilt scales use a four-point Likert
rating, in which the parent notes whether over the past 6
months the behavior symptoms have occurred rarely, sometimes,
often, or very often. Higher scores indicate more severe ADHD symp-
tomatology.
PedsQL Family Information Form
Parents completed the PedsQL Family Information Form [27],
which contains demographic information such as the child’s date
of birth, sex, race/ethnicity, and parental education and occupa-
tion information required to calculate the Hollingshead Socioeco-
nomic Status (SES) Index [39]. Mean Hollingshead Index scores
between 66 and 55 indicates upper class, 54 to 40 indicates upper-
middle class, 39 to 30 indicates middle class, 29 to 20 indicates
lower-middle class, and 19 to 8 indicates lower class.
Disease-specific indicators
The following information was retrieved from the child’s medical
chart by a research nurse: number of months since ADHD diagno-
sis, number of psychiatric diagnoses, category of comorbid diag-
noses, number of daily psychiatric medications, and number of
months on psychiatric medications.
Procedures
Data collection for the ADHD and comorbid psychiatric disorders
sample took place over a 3-year period between 2005 and 2008.
ADHD and comorbid psychiatric diagnoses were made after an
extensive clinical interview by a child psychiatrist before the child
was enrolled in the study based on signs and symptoms presented
and history, including in some cases diagnostic scales completed
by parents and teachers. Children ages 5 to 18 years and their
parents were given a specific PedsQL 4.0 Generic Core Scales age-
appropriate form depending on the child’s age (5 to 7 years, 8 to 12
years, and 13 to 18 years). Younger children (5 to 7 years) were
assisted by a research assistant in completing the measure. The
research assistant was also available to assist children in the older
groups and parents as needed. All research assistants were
trained using a detailed protocol to ensure administration of the
questionnaires was standardized across the sample. After com-
pleting the PedsQL 4.0 Generic Core Scales, parents completed the
Vanderbilt ADHD Diagnostic Rating Scales Parent Version and the
PedsQL Family Information Form, in that order. Participants com-
pleted instruments in a patient examination room in the Pediatric
Psychiatric Clinic, either while waiting for the physician or after
the child’s appointment with the physician. Each child/parent pair
was provided a $10 gift certificate for their participation in the
study. Written parental informed consent and child assent for
children ages 7 years and older were obtained. This research pro-
tocol was approved by the institutional review board at Scott and
White Memorial Hospital and Clinics.
The healthy children sample was derived from the previously
conducted PedsQL 4.0 Generic Core Scales initial field test [27] and
a statewide State Children’s Health Insurance Program evaluation
[40]. Children were assessed either in physicians’ offices during
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524 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 2 1 – 5 3 0well-child visits, by telephone, or via a statewide mailing. The
pediatric cancer sample was derived from the PedsQL 3.0 Cancer
Module field test [41]. Children and their parents were assessed
in-person by a research assistant at two pediatric cancer centers.
The type 1 diabetes sample was derived from the PedsQL 3.0 Dia-
betes Module field test [42] and a subsequent study in a hospital-
based pediatric endocrinology clinic [43]. Children and their par-
ents were assessed in-person by a research assistant at the
pediatric endocrinology clinics or via telephone. Across the
healthy, cancer, and diabetes samples, both child self-report and
parent proxy-report versions of the PedsQL 4.0 Generic Core Scales
were utilized. These research protocols were approved by the ap-
propriate local institutional review boards.
Statistical analyses
Feasibility of the PedsQL 4.0 Generic Core Scales as a PRO mea-
sure for pediatric patients with ADHD and comorbid psychiatric
disorders was determined from the percentage of missing val-
ues for each item [44]. To determine scale internal consistency
reliability, Cronbach’s coefficient alphas were calculated [45].
cales with reliabilities of 0.70 or greater are recommended for
omparing patient groups, while a reliability criterion of 0.90 is
ecommended for analyzing individual patient scale scores
46,47]. Range of measurement was based on the percentage of
cores at the extremes of the scaling range, that is, the maxi-
um possible score (ceiling effect) and the minimum possible
core (floor effect) [44]. Surveys with small floor or ceiling effects
1–15%) are considered to meet acceptable measurement stan-
ards, whereas surveys with moderate floor or ceiling effects
more than 15%) are considered less precise in measuring latent
onstructs at the extremes of the scale [48].
Discriminant validity for the PedsQL 4.0 Generic Core Scales
as determined utilizing the known-groups method [49]. The
known-groups method compares scale scores across groups
known to differ in the health construct being investigated. In-
dependent samples t tests were used to compare pediatric pa-
tients with ADHD and comorbid psychiatric disorders to a
matched sample of healthy children on the PedsQL 4.0 Generic
Core Scales. The healthy children sample was randomly
matched by age, sex, and race/ethnicity to the ADHD and co-
morbid psychiatric disorders sample utilizing the SPSS version
16.0 statistical software random sample case selection com-
mand. This command allows the percentage of children in the
healthy sample to be matched to the ADHD sample on the tar-
geted demographic characteristics. Effect sizes were calculated
in order to determine the magnitude of the differences between
pediatric patients with ADHD and healthy children [50]. Effect
size as utilized in these analyses was calculated by taking the
difference between the healthy sample mean and the ADHD
sample mean, divided by the pooled standard deviation. Effect
sizes for differences in means are designated as small (0.20),
medium (0.50), and large (0.80) in magnitude [50]. PedsQL com-
parisons were also explored between pediatric patients with
ADHD and comorbid psychiatric disorders and pediatric pa-
tients with cancer and type 1 diabetes utilizing independent
sample t tests. The type I error rate was set at 0.008 (0.05 of 6) by
he Bonferroni adjustment for multiple comparisons; adjust-
ents were made separately for patient self-report and parent
roxy-report for each comparison.
An analysis of Pearson’s Product Moment Correlations
among the PedsQL 4.0 Generic Core Scales and the National
Initiative for Children’s Healthcare Quality Vanderbilt Scales, as
well as disease-specific indicators, including number of months
since diagnosis, number of diagnoses, number of daily medica-
tions, and number of months on medications, were examined.
Based on the conceptualization of disease-specific symptoms as
causal indicators of generic HRQOL, it was anticipated thatmore severe ADHD symptoms would be associated with more
impaired PedsQL scale scores. Pearson’s Product Moment Cor-
relation coefficient effect sizes are designated as small (0.10 –
0.29), medium (0.30 – 0.49), and large (0.50 or greater) [50].
Intraclass correlation coefficients (ICCs) were utilized to
evaluate agreement between patient self-report and parent
proxy-report on the PedsQL scales. [51]. The ICC provides an
index of absolute agreement given that it takes into account the
ratio between subject variability and total variability [51,52].
Intraclass Correlations are designated as 0.40 or less poor to fair
agreement, 0.41 to 0.60 moderate agreement, 0.61– 0.80 good
agreement, and 0.81–1.00 excellent agreement [53,54]. In addi-
tion, mean values between patient and parent scores on the
PedsQL 4.0 Generic Core Scales were compared using paired
sample t tests. To determine the magnitude of the differences
between pediatric patients with ADHD and their parents, effect
sizes were calculated [50]. Effect size as utilized in these analy-
ses were calculated by taking the difference between the child
mean and the parent sample mean, divided by the pooled SD. As
previously noted, effect sizes for differences in means are des-
ignated as small (0.20), medium (0.50), and large (0.80) in mag-
nitude [50]. Statistical analyses were conducted using SPSS ver-
sion 16.0 for Windows [55].
Results
Sociodemographic characteristics
ADHD and comorbid psychiatric disorders sample
The mean age of the 57 girls (31.1%) and 124 boys (67.8%; missing,
n  2, 1.1%) was 11.08  3.70 years. In terms of race/ethnicity, the
sample contained 147 (80.3%) white non-Hispanic, 8 (4.4%) His-
panic, 20 (10.9%) black non-Hispanic, 5 (2.7%) other, and 3 (1.6%)
missing. Mean SES was 40.62 11.71, indicating on average a mid-
dle to upper middle class sample based on the Hollingshead Index
[39]. The comorbid diagnoses included mood disorders (n  82),
disruptive behavior disorders (n  99), anxiety disorders (n  52),
psychotic disorders (n 7), substance use disorders (n 1), learn-
ing disability/mental retardation (n 28), and other (n  13). The
median number of daily psychiatric medications children in the
sample were taking was 1  0.57; range 0–3). Mean number of
months children had been on psychiatric medications was 42.09
31.71; range 1–153). More than 98% of patients in the sample were
taking at least one daily psychiatric medication (44.8% of the sam-
ple were taking two daily psychiatric medications, 3.8% of the
sample were taking three daily psychiatric medications).
Healthy sample
The mean age of the 957 boys (65.9%) and 496 girls (34.1%) was 9.21
 4.46 years. In terms of race/ethnicity, the sample contained 1170
(80.5%) white non-Hispanic, 112 (7.7%) Hispanic, 131 (9.0%) black
non-Hispanic, 26 (1.8%) other, and 14 (1.0%) missing. Mean SES was
unavailable for this sample, although the statewide State Chil-
dren’s Health Insurance Program. The sample was representative
of low-income families (less than 250% of the federal poverty
level).
Pediatric cancer sample
The sample included pediatric cancer patients on cancer treatment
(chemotherapy and radiation) with acute lymphocytic leukemia (n
18, 64.5%), brain tumors (n8, 4.4%) non-Hodgkin’s lymphoma (n
, 4.9%), Hodgkin’s lymphoma (n  6, 3.3%), Wilms’ tumor (n  7,
.8%), and other cancers (n 35, 19.1%). For all forms combined, the
verage age of the 107 boys (58.5%) and 75 girls (41.0%; missing  1,0.5%) was 8.22  4.83 years. The sample was heterogeneous with
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(49.7%) Hispanic, 8 (4.4%) black non-Hispanic, 10 (5.5%) Asian/Pacific
Islander, 1 (0.5%) American Indian or Alaskan Native, and 2 (1.1%)
missing.
Pediatric type 1 diabetes sample
For all participants combined, the mean age of the 172 girls (53.8%)
and 148 boys (46.3%) was 12.34  3.94 years. With regard to race/
ethnicity, the sample contained 193 (60.3%) white non-Hispanic,
62 (19.4%) Hispanic, 25 (7.8%) black non-Hispanic, 12 (3.8%) Asian/
Pacific Islander, and 28 (8.8%) other or missing.
Measurement properties
Feasibility
For patient self-report and parent proxy-report, the percentage of
missing item responses for the ADHD and comorbid psychiatric
disorders sample on the PedsQL 4.0 Generic Core Scales was 0.2%
and 0.5%, respectively.
Range of measurement
Table 1 contains the percentage of scores at the extremes of the
scaling range (floor and ceiling effects). There was no significant
floor or ceiling effects for any of the summary or scale scores for
patient self-report and parent proxy-report.
Internal consistency reliability
Table 1 presents the internal consistency reliability alpha coeffi-
cients for the ADHD and comorbid psychiatric disorders sample on
the PedsQL 4.0 Generic Core Scales. All patient self-report scales
and parent proxy-report scales on the Generic Core Scales, with
the exception of the School Functioning Scale for patient self-
report (  0.65), met or exceeded the minimum reliability stan-
Table 1 – Pediatric Quality of Life Inventory™ (PedsQL) 4.0
proxy-report across samples and reliability for attention-d
psychiatric disorders sample.
PedsQL Scales ADHD/comorbid psychiatri
‡ Mean SD % Fl
(n  179)
Patient self-report
Total score 0.85 67.00 15.80 0.
Physical Health 0.71 76.59 17.60 0.
Psychosocial Health 0.81 61.89 17.57 0.
Emotional Functioning 0.72 59.16 23.41 0.
Social Functioning 0.75 66.73 24.86 1.
School Functioning 0.65 59.99 20.55 0.
(n  181)
Parent proxy-report
Total score 0.92 58.38 18.04 0.
Physical Health 0.89 70.77 24.44 0.
Psychosocial Health 0.90 51.76 17.87 0.
Emotional Functioning 0.79 48.36 20.39 1.
Social Functioning 0.85 58.87 22.96 0.
School Functioning 0.78 48.00 19.40 0.
SD, standard deviation.
*** P  0.001 based on independent sample t tests (Bonferroni adjust
† Effect sizes are designated as small (0.20), medium (0.50), and large
‡ , Cronbach internal consistency reliability coefficient alpha.ard of 0.70 required for group comparisons. The total score foroth patient self-report and parent proxy-report met or ap-
roached the reliability criterion of 0.90 recommended for analyz-
ng individual patient scale scores.
Discriminant validity
Mean comparison to matched healthy sample
Means and SDs of the PedsQL 4.0 Generic Core Scale Scores for
patient self-report and parent proxy-report are presented in Ta-
ble 1. For all PedsQL 4.0 Generic Core Scales, pediatric patients
with ADHD and comorbid psychiatric disorders and their par-
ents reported statistically significant worse PedsQL scores than
healthy children. All effect sizes were in the large range, with
the greatest effects for both patients self-report and parent
proxy-report found on the Psychosocial Health Summary Score.
It should be noted that the large effect sizes reported between
our sample and healthy children on the Physical Health Sum-
mary Score was not an anticipated finding. A post-hoc analysis
of responses to individual items on the PedsQL Physical Health
Summary Score in the current sample revealed that 11.7% of the
patients self-reported “often” or “almost always” having low
energy, whereas 14.5% of the patients self-reported “often” or
“almost always” having hurts or aches; 19.9% of parents re-
ported their child “often” or “almost always” had low energy,
while 26.5% of parents reported their child “often” or “almost
always” had hurts or aches.
Mean comparisons to pediatric cancer and diabetes
Table 2 presents PedsQL 4.0 Generic Core Scales Scores for pe-
diatric patients with cancer and type 1 diabetes. Pediatric pa-
tients with ADHD and comorbid psychiatric disorders self-
reported significantly lower PedsQL scale scores than pediatric
patients with type 1 diabetes across all PedsQL 4.0 Generic Core
ric Core Scales for patient self-report and parent
/hyperactivity disorder (ADHD) and comorbid
orders Healthy Mean
differences
Effect
size†
% Ceiling Mean SD
(n  876)
0.0 85.86 11.76 18.86*** 1.50
7.7 90.09 11.58 13.50*** 1.05
1.1 83.62 13.47 21.73*** 1.53
7.1 81.99 17.16 22.83*** 1.24
11.5 87.25 15.63 20.52*** 1.17
6.0 81.66 15.92 21.67*** 1.29
(n  1443)
0.5 86.04 12.72 27.66*** 2.06
12.6 89.33 15.20 18.56*** 1.13
0.5 84.19 13.45 32.43*** 2.31
1.6 82.39 15.58 34.03*** 2.07
4.4 88.01 15.58 29.14*** 1.76
4.4 81.41 17.61 33.41*** 1.88
for multiple comparisons equals 0.008).
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526 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 2 1 – 5 3 0social health. Pediatric patients with ADHD and comorbid psy-
chiatric disorders self-reported significantly lower PedsQL scale
scores than pediatric patients with cancer on treatment on psy-
chosocial health, emotional functioning, social functioning,
and school functioning; they self-reported a comparable Total
Score and significantly higher Physical Health Summary Score
than pediatric cancer patients. Parents of pediatric patients
with ADHD and comorbid psychiatric disorders reported signif-
icantly lower PedsQL scale scores for their children than parents
of pediatric patients with cancer and type 1 diabetes across all
PedsQL 4.0 Generic Core Scales, with the exception of physical
health in which parents of pediatric patients with cancer re-
ported significantly lower physical health for their children.
Associations with disease indicators
Table 3 shows the intercorrelations among the PedsQL 4.0 Ge-
neric Core Scales, the Vanderbilt Scales, and disease-specific
indicators for the ADHD and comorbid psychiatric disord-
ers sample. Intercorrelations between patients self-reported
PedsQL 4.0 Generic Core Scales and the parent proxy-reported
Vanderbilt Total ADHD Symptom Score were generally not sta-
tistically significant. The only intercorrelation that was signifi-
cant between the patient self-reported PedsQL 4.0 Generic Core
Scales and parent proxy-reported Vanderbilt Total ADHD Symp-
tom Score was evidenced on the School Functioning Scale (r 
0.16, P  0.05). The patient self-reported PedsQL School Func-
ioning Scale was also significantly negatively correlated with
umber of diagnoses (r  0.27, P  0.001), number of months
n medicines (r  0.21, P  0.01), and number of months since
iagnosis (r  0.20, P  0.01). The patient self-reported PedsQL
sychosocial Health Summary Score was significantly nega-
ively correlated with number of diagnoses (r  0.18, P  0.05).
ll of the patient self-report intercorrelations were in the small
Table 2 – Pediatric Quality of Life Inventory™ (PedsQL) 4.0
attention-deficit/hyperactivity disorder (ADHD) and comorb
pediatric cancer patients on treatment and pediatric patien
PedsQL Scales ADHD/
comorbid
psychiatric
disordersa
Cancer (on
treatment)b
Mean SD Mean SD
(n  179) (n  105 )
Patient self-report
Total score 67.00 15.80 68.92 15.97
Physical Health 76.59 17.60 65.54 23.14
Psychosocial Health 61.89 17.57 71.04 15.17
Emotional Functioning 59.16 23.41 68.81 21.24
Social Functioning 66.73 24.86 77.19 18.29
School Functioning 59.99 20.55 66.22 19.60
(n  181) (n  180)
Parent proxy-report
Total score 58.38 18.04 66.95 19.85
Physical Health 70.77 24.44 65.00 26.26
Psychosocial Health 51.76 17.87 68.19 18.25
Emotional Functioning 48.36 20.39 63.26 20.70
Social Functioning 58.87 22.96 75.58 20.08
School Functioning 48.00 19.40 63.61 24.03
* P 0.05, ** P 0.01, *** P 0.001 based on independent samples t tes
be considered statistically significant).
 Effect sizes are designated as small (0.20), medium (0.50), and largeffect size range (r  0.30).All parent proxy-reported PedsQL 4.0 Generic Scales were
ignificantly correlated with the parent proxy-reported Vander-
ilt Total ADHD Symptom Score, with the largest intercorrela-
ions demonstrated on psychosocial health (r0.56, P 0.001)
nd school functioning (r  0.52, P  0.001). Pearson’s product
oment correlations between the parent proxy-reported PedsQL
.0 Generic Core Scales and parent proxy-reported Vanderbilt To-
al ADHD Symptom Score were all in the medium to large effect
ize range. Number of diagnoses was also significantly correlated
ith all parent proxy-reported PedsQL 4.0 Generic Core Scales,
ith the largest intercorrelation found on psychosocial health (r
0.33, P  0.001). Parent proxy-reported PedsQL psychosocial
ealth and school functioning were significantly correlated with
umber of daily medicines (r0.17, P 0.05; r0.17, P 0.05),
umber of months on medicines (r0.19, P 0.05; r0.19, P
.05), and number of months since diagnosis (r  0.19, P  0.05;
 0.18, P  0.05).
Parent/child agreement
ICCs between pediatric patient self-report and parent proxy-
report for the ADHD and comorbid psychiatric disorders sample
across the PedsQL 4.0 Generic Core Scales are presented in Table
4. These ICCs are in the poor to fair agreement range. The great-
est agreement was found between children and parents on
school functioning, whereas the lowest agreement was demon-
strated between children and their parents on physical health.
Mean scores for the 177 children with ADHD and comorbid
psychiatric disorders and their parents who both completed the
PedsQL 4.0 Generic Core Scales are presented in Table 5. Across all
PedsQL scales, children self-reported significantly higher HRQOL
than their parents, with the greatest differences evidenced on
school functioning (effect size 0.61) and psychosocial health (effect
ric Core Scales for pediatric patients with
sychiatric disorders sample and comparisons with
ith type 1 diabetes.
Type 1
diabetesc
Mean
differences
Effect size
a vs. b
Effect size
a vs. c
ean SD
(n  292 )
0.79 12.78 a  c*** 0.12 0.98
5.80 13.16 a  c***; a  b*** 0.56 0.61
8.06 14.55 a  b, c*** 0.55 1.03
4.16 19.77 a  c***; a  b** 0.43 0.71
5.93 16.42 a  b, c*** 0.46 0.96
4.27 18.16 a  c***; a  b* 0.31 0.75
(n  310 )
7.48 14.33 a  b, c*** 0.45 1.21
2.19 17.97 b  a*; a  c*** 0.23 0.55
4.91 15.12 a  b, c*** 0.91 1.43
0.38 18.35 a  b, c*** 0.73 1.15
2.81 18.49 a  b, c*** 0.77 1.18
1.35 19.04 a  b, c*** 0.72 1.22
ith a Bonferroni correction only values significant at P 0.008 should
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The primary objective of this study was to evaluate the mea-
surement properties of patient self-reported PedsQL 4.0 Generic
Core Scales scores in pediatric patients with ADHD and physi-
cian-diagnosed comorbid psychiatric disorders being seen in a
pediatric psychiatric clinic. These findings support the feasibil-
ity, reliability, and validity of the pediatric patient self-reported
PedsQL 4.0 Generic Core Scales in this population of pediatric
patients at risk for significantly impaired HRQOL. The PedsQL
4.0 Generic Core Scales evidenced minimal missing responses
for patient self-report, demonstrating that pediatric patients
with ADHD and comorbid psychiatric disorders are willing and
able to provide good quality data regarding their generic HRQOL.
Range of measurement was demonstrated, with no significant
floor or ceiling effects across the PedsQL summary or scales
scores. Internal consistency reliabilities exceeded the mini-
mum standard of 0.70 for group comparisons for all scales ex-
Table 3 – Intercorrelations among Pediatric Quality of Life
disease-specific indicators for pediatric patients with atten
psychiatric disorders.
PedsQL Scales Vanderbilt
ADHD
symptom
score
Vanderbilt
inattentive
scale
Vand
hyper
impu
sc
Patient self-report
Total score 0.12 0.16* 0.
Physical Health 0.04 0.06 0.
Psychosocial Health 0.15 0.19* 0.
Emotional Functioning 0.04 0.07 0.
Social Functioning 0.13 0.09 0.
School Functioning 0.16* 0.29*** 0.
Parent proxy-report
Total score 0.51*** 0.55*** 0.
Physical Health 0.33*** 0.37*** 0.
Psychosocial Health 0.56*** 0.59*** 0.
Emotional Functioning 0.48*** 0.47*** 0.
Social Functioning 0.44*** 0.45*** 0.
School Functioning 0.52*** 0.61*** 0.
Effect sizes are designated as small (0.10), medium (0.30), and large (0
* P  0.05, ** P  0.01, *** P  0.001.
Table 4 – Intraclass correlation coefficients (ICC) between
pediatric patient self-report and parent proxy-report for
the attention-deficit/hyperactivity disorder and comorbid
psychiatric disorders sample.
Parent-child agreement
ICCs† (n  177)
PedsQL scales
Total score 0.24***
Physical Health 0.13*
Psychosocial Health 0.30***
Emotional Functioning 0.19***
Social Functioning 0.29***
School Functioning 0.35***
* P  0.05, ** P  0.01, *** P  0.001.
† ICCs are designated as 0.40 poor to fair agreement, 0.41–0.60
moderate agreement, 0.61–0.80 good agreement, and 0.81–1.00[
excellent agreement.cept school functioning for patient self-report. The PedsQL To-
tal Scale Score met or approached an  of 0.90 recommended for
individual patient analysis for patient self-report, making the
Total Scale Score suitable as a summary score for the primary
analysis of generic HRQOL in clinical trials for pediatric patients
with ADHD and comorbid psychiatric disorders.
As anticipated, pediatric patients with ADHD and comorbid
psychiatric disorders demonstrated significantly lower psycho-
social health than a matched sample of healthy children, with
large effect sizes supporting discriminant validity. However, we
also found large effects between pediatric patients with ADHD
and healthy children on physical health in contrast to previous
studies of pediatric patients with ADHD on this dimension
[13,20]. Our findings may in part be attributed to differences in
symptom severity between our sample and the previous sam-
ples. Our sample consisted of children with ADHD and comor-
bid psychiatric disorders being treated at a psychiatric clinic
(98.4% of children were taking at least one daily medication to
treat symptoms). Children with ADHD in the Varni and Bur-
winkle study [13] were from a population-based sample (comor-
bid diagnoses and medication use were unknown). Children
from the Klassen et al. study [20] were from an ADHD clinic;
owever, according to the authors, one-third of the sample was
ewly identified by family doctors and not necessarily complex
only 27.5% of children in the sample were taking ADHD medi-
ations).
There is empirical literature that has shown that after ad-
usting for measures of global disadvantage (i.e., poverty, care-
aker’s education, parental marital status, number of diagnoses
ther than ADHD) the correlation between ADHD and physical
ealth problems was significant for children with ADHD seen in
reatment facilities [56]. This may in part be attributed to the
act that children with ADHD seen in treatment facilities are
ften treated with stimulant medications which can have side
ffects that affect physical functioning (i.e., loss of appetite,
eadaches, and stomachaches). Furthermore, children with
DHD seen in treatment facilities are more likely to have co-
orbid psychiatric disorders such as depression and anxiety
hat have known physical effects, including fatigue and pain
tory™ (PedsQL) 4.0 Generic Core Scales and
-deficit/hyperactivity disorder (ADHD) and comorbid
t
e-
Number of
diagnoses
Number of
daily
medicines
Number of
months on
medicines
Number of
months
since
diagnosis
0.12 0.02 0.05 0.05
0.03 0.05 0.07 0.08
0.18* 0.06 0.11 0.10
0.07 0.03 0.06 0.07
0.12 0.03 0.02 0.00
0.27*** 0.08 0.21** 0.20**
0.31*** 0.09 0.19* 0.19*
0.21** 0.04 0.13 0.14
0.33*** 0.17* 0.19* 0.19*
0.27*** 0.20** 0.10 0.12
0.29*** 0.06 0.20** 0.19*
0.28*** 0.17* 0.19* 0.18*
or Pearson’s product moment correlations.Inven
tion
erbil
activ
lsive
ale
09
01
13
04
16*
07
37***
24**
40***
39***
34***
31***
.50) f57]. Thus, our finding that children with ADHD and healthy
(0.80
528 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 2 1 – 5 3 0children evidenced large effect sizes on physical health from
the perspective of both pediatric patients and parents may in
part be a function of the more severe nature of our sample and
accompanying comorbid psychiatric disorders.
Previously we demonstrated that children with ADHD
treated in a general pediatric clinic manifested better PedsQL
4.0 Generic Core Scales scores than pediatric patients with
ADHD with physician-diagnosed psychiatric comorbid psychi-
atric disorders treated in a pediatric psychiatric clinic [58]. The
additional comparisons in the present study between patients
with ADHD and comorbid psychiatric disorders with pediatric
patients with cancer on-treatment and those children with type
1 diabetes are important in further understanding the profound
negative impact of ADHD and comorbid psychiatric disorders
on patient reported PedsQL 4.0 Generic Core Scales scores.
The finding that only one patient self-reported PedsQL Scale
(school functioning) was significantly correlated with the Van-
derbilt Total ADHD Symptom Score (compared to all parent
proxy-reported PedsQL Scales) may in part be a function of
shared method variance for parent proxy-report, and is consis-
tent with the general pediatric HRQOL literature that pediatric
patient and parent perspectives provide different, but equally
important, sources of information regarding patient function-
ing [25].
This study has a number of potential limitations. Data were
pooled across age forms given that sample sizes for each age
form were not large enough to conduct separate analyses. Fur-
thermore, there was variability within our sample with regard
to disease-specific indicators such as time since diagnosis and
time on medications. There was no standardized protocol for
diagnosing a child with ADHD or comorbid psychiatric disorders
in our study. However, ADHD and comorbid psychiatric diagno-
ses were made by a child psychiatrist before the child was en-
rolled in the study based on signs and symptoms presented and
history, including in some cases diagnostic scales completed by
parents and teachers. We did not have information on the exact
comorbid psychiatric disorders patients in our sample had, but
rather the diagnostic category. Our sample was predominantly
white males, which may further limit the generalizability of the
findings. However, it should be noted that in terms of sociode-
mographics, our sample was representative of the underlying
population of children with ADHD in the United States, which is
more likely to be white males [59]. The cancer and type 1 diabe-
tes samples came from an existing database and consequently
Table 5 – Comparisons between Pediatric Quality of Life In
patient self-report and parent proxy-report for the attentio
disorders sample.
PedsQL Scales Pediatric patient
self-report
Mean SD
(n  177)
Total score 66.99 15.88
Physical health 76.45 17.65
Psychosocial health 61.94 17.66
Emotional functioning 59.27 23.52
Social functioning 66.61 24.96
School functioning 60.16 20.59
SD, standard deviation.
* P  0.05, ** P  0.01, *** P  0.001 based on paired sample t tests (w
considered statistically significant).
† Effect sizes are designated as small (0.20), medium (0.50), and largewe were not able to match these samples to the ADHD sampleon sociodemographic characteristics given sample size limita-
tions. This was a cross-sectional study, thus it provided only a
snapshot of PedsQL scale scores at one time point. Finally,
ADHD symptom severity was measured only from the perspec-
tive of parents in our study.
Implications for research, policy, and practice
These findings have several implications for future research and
clinical practice with pediatric patients with ADHD and comorbid
psychiatric disorders. First, given the large effect sizes reported
between our sample and healthy children on physical health, it is
important that interventions designed for children with ADHD
and comorbid psychiatric disorders not only address psychosocial
difficulties, but also the physical impairments that may result
from medications and/or comorbid psychiatric disorders such as
anxiety or depression. The findings suggest that the constructs of
fatigue and pain may be important to address in future interven-
tions with this population. It will be beneficial for future research
to elucidate the relationship between fatigue, pain, and generic
PedsQL scale scores so that more efficacious interventions can be
developed. Given the growing body of literature that suggests chil-
dren with ADHD experience chronic sleep difficulties [60], future
research should also investigate the relationship between sleep
deficits and physical health in children with ADHD and comorbid
psychiatric disorders.
The finding that pediatric patients and their parents demon-
strated poor to fair agreement regarding the child’s PedsQL
scale scores underscores the importance of evaluating both
children’s and parents’ perspectives regarding generic HRQOL
in routine assessment in clinical practice and clinical trials for
children with ADHD and comorbid psychiatric disorders be-
cause their different perspectives potentially provide unique
information. Discrepancies between patient and parent reports
of the child’s PedsQL scale scores can be used clinically to facil-
itate communication between parents and children. For exam-
ple, if a child reports that “almost always” other kids tease him/
her and his mother reports that the child “never” gets teased by
other children, this would be an opportunity for the child’s
health-care provider to intervene and discuss these differences
in perspective with the child and parent. A number of studies
with children with chronic health conditions have reported
greater agreement between parents and children on physical
functioning because this is a more observable construct [61].
ory™ (PedsQL) 4.0 Generic Core Scales for pediatric
ficit/hyperactivity disorder and comorbid psychiatric
Parent
proxy-report
Mean
differences
Effect size†
n SD
2 18.19 8.57*** 0.50
0 24.61 5.55* 0.26
6 18.02 10.18*** 0.57
5 20.61 10.92*** 0.49
9 22.99 7.82*** 0.33
0 19.23 12.06*** 0.61
Bonferroni correction only values significant at P  0.008 should be
).vent
n-de
Mea
58.4
70.9
51.7
48.3
58.7
48.1
ith aThe finding that agreement was lowest between parents and
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529V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 2 1 – 5 3 0children on physical health in our sample further demonstrates
the need for future research to investigate the construct of
physical health in pediatric patients with ADHD and comorbid
psychiatric disorders. Future studies should also evaluate the
factors that influence parent– child discordance in this popula-
tion of patients with severely impaired PedsQL scale scores.
Source of financial support: Data collection was supported by
an intramural grant from the Scott and White Memorial Hospital
Research Foundation.
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